Positive recommendation based on phase III INAVO120 data showing ItovebiTM (inavolisib) in combination with palbociclib and ...

Itovebi (inavolisib) has been dealt a boost after the drug demonstrated further positive overall survival (OS) data in a ...

Basel: Roche has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

Roche, hoping to carve out a standard-of-care spot for its PI3K inhibitor Itovebi, now has another leg to stand on with new ...

Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said that an advisory panel of the European Medicines Agency (EMA), endorsed its Itovebi ...

The Itovebi-based regimen is approved for the treatment ... as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company ...

The Itovebi-based regimen is approved for the treatment ... For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution ...